Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN67038373
ISRCTN67038373
Completed
Phase 2

Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH)

niversity of Nottingham0 sites54 target enrollmentStarted: October 22, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHaemorrhagic strokeCirculatory SystemIntracerebral haemorrhage

Overview

Phase
Phase 2
Status
Completed
Sponsor
niversity of Nottingham
Enrollment
54
OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33172941/ Peer reviewed protocol article (added 11/08/2022) 2023 Results article in https://doi.org/10.1016/S1474-4422(23)00157-6 (added 22/06/2023)

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Current participant inclusion criteria as of 12/02/2020:
  • •1\. Aged \>18 years
  • •2\. Confirmed intracerebral hemorrhage on imaging
  • •3\. Less than 24 hours from onset of symptoms (or from when last seen healthy)
  • •4\. Prescribed and thought to be taking a daily oral antiplatelet drug in the preceding seven days (cyclooxygenase inhibitors, phosphodiesterase inhibitors or P2Y12 inhibitors)
  • •5\. Signed consent (patient/personal/professional representative)
  • •Previous participant inclusion criteria:
  • •1\. Adults (\>17 years)
  • •2\. Confirmed intracerebral haemorrhage on imaging
  • •3\. Less than 12 hours from onset of symptoms \[or from when last seen healthy]

Exclusion Criteria

  • •1\. Aneurysmal subarachnoid haemorrhage known at time of enrolment
  • •2\. Haemorrhage known to be due to transformation of infarction
  • •3\. Haemorrhage known to be due to thrombolytic drug
  • •4\. Haemorrhage known to be due to venous thrombosis
  • •5\. Risk/s of fluid retention associated with desmopressin judged clinically significant by the attending physician (for example patients with pulmonary oedema and/or cardiac failure)
  • •6\. Significant hypotension (systolic blood pressure \< 90mmHg)
  • •7\. Known drug\-eluting coronary artery stent in previous three months
  • •8\. Allergy to desmopressin
  • •9\. Pregnant or breastfeeding
  • •10\. Life expectancy less than four hours, or planned for palliative care only

Investigators

Sponsor
niversity of Nottingham

Similar Trials

Active, not recruiting
Phase 1
A trial to assess whether desmopressin could reduce risk of death or disability for patients with intracerebral haemorrhage (bleeding into the brain) taking antiplatelet (blood thinning ) drugs. study will be modified Rankin scale at day 90 (shift analysis).Intracerebral haemorrhageMedDRA version: 21.1 Level: PT Classification code 10019016 Term: Haemorrhagic stroke System Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2018-001904-12-GBniversity of Nottingham50
Completed
Phase 2
Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to HaemorrhageStroke, Acute
NCT03696121University of Nottingham54
Unknown
Phase 4
Desmopressin for Bleeding Related to Low Body TemperatureHypothermia Induced Impairment of Primary Haemostasis
NCT00902057The University of Hong Kong48
Unknown
Phase 4
Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve SurgeryC.Surgical Procedure; CardiacBlood Coagulation Disorders
NCT03343418Instituto do Coracao108
Completed
Phase 2
The evaluation efficacy of Desmopressin in improvement coagulation status of patients with combined factor V and VIII deficiency.
IRCT2015020120894N1Vice chancellor for research, Mashhad University of Medical Sciences24